Dr. Jacques Moisan is Vice President and Head of Oncology and Translational Sciences at Actithera, where he leads oncology research and translational science efforts supporting the company’s radioligand therapy pipeline. He brings extensive drug development using small molecules and biologic modalities across multiple therapeutic areas including oncology and rheumatology spanning both biotechnology and pharmaceutical organizations. Prior to joining Actithera, Jacques held scientific leadership roles at Marengo Therapeutics, EMD Serono, Lycera, and AstraZeneca, where he led discovery and translational programs with a focus on cancer immunotherapy. He earned his PhD in Immunology from McGill University.